- Report
- February 2024
- 250 Pages
Global
From €4815EUR$5,000USD£4,141GBP
- Report
- February 2024
- 250 Pages
Global
From €4815EUR$5,000USD£4,141GBP
- Report
- October 2023
- 180 Pages
Global
From €4719EUR$4,900USD£4,058GBP
- Clinical Trials
- April 2024
- 80 Pages
Global
From €1926EUR$2,000USD£1,656GBP
- Drug Pipelines
- April 2024
- 220 Pages
Global
From €2408EUR$2,500USD£2,071GBP
- Clinical Trials
- April 2024
- 50 Pages
Global
From €1445EUR$1,500USD£1,242GBP
- Report
- October 2023
- 181 Pages
Global
From €4719EUR$4,900USD£4,058GBP
- Report
- July 2023
- 218 Pages
Global
From €4334EUR$4,500USD£3,727GBP
- Report
- October 2023
- 85 Pages
United States
From €4574EUR$4,750USD£3,934GBP
- Report
- March 2018
- 300 Pages
Global
From €2311EUR$2,400USD£1,988GBP
- Report
- October 2022
- 270 Pages
Global
From €3611EUR$3,750USD£3,106GBP
- Report
- July 2018
- 15 Pages
Global
- Report
- August 2022
- 111 Pages
Global
From €4574EUR$4,750USD£3,934GBP
- Report
- June 2022
- 120 Pages
Global
From €4574EUR$4,750USD£3,934GBP
- Report
- September 2022
- 282 Pages
Global
From €9149EUR$9,500USD£7,868GBP
- Report
- February 2022
- 210 Pages
Global
From €7223EUR$7,500USD£6,212GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2648EUR$2,750USD£2,278GBP
- Report
- February 2022
- 228 Pages
Global
From €7223EUR$7,500USD£6,212GBP
- Report
- January 2022
- 60 Pages
Global
From €1926EUR$2,000USD£1,656GBP
- Report
- August 2022
- 118 Pages
Global
From €4334EUR$4,500USD£3,727GBP
Etanercept is a biologic drug used to treat immune disorders such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. It is a recombinant fusion protein that works by blocking the action of tumor necrosis factor (TNF), a protein involved in inflammation. Etanercept is administered by subcutaneous injection and is available in both brand name and generic forms.
Etanercept is a widely used drug in the treatment of immune disorders, and is often prescribed in combination with other medications. It is generally well tolerated, with the most common side effects being injection site reactions, headache, and upper respiratory tract infections.
The etanercept market is highly competitive, with several major players. These include Amgen, Pfizer, AbbVie, and Johnson & Johnson. Other companies in the market include Biogen, Merck, and Novartis. Show Less Read more